Sermorelin: GHRH(1-29) Research Overview

Sermorelin is the synthetic 29-amino-acid N-terminal fragment of human growth hormone-releasing hormone, often written GRF(1-29). This fragment retains the receptor-binding region responsible for GHRH activity, which is why it functions as a GHRH-receptor agonist despite being shorter than the native 44-residue hormone.

Because it acts on the pituitary rather than replacing growth hormone, sermorelin's measurable effect in research settings is a stimulated GH response — the size of which depends on pituitary responsiveness in the model or population being studied.

Much of the useful sermorelin literature is diagnostic. Studies using GHRH(1-29) as a stimulation agent have examined how pituitary GH responsiveness varies across conditions. A 2000 study in the European Journal of Endocrinology reported that the GH response to low-dose bolus GHRH(1-29) was attenuated in patients with longstanding post-irradiation GH insufficiency. A 2006 study in Clinical Endocrinology examined impaired GH responsiveness to combined GHRH and arginine administration in adults with Prader-Willi syndrome.

Broader context comes from review literature: a 1993 Endocrine Reviews article by Corpas, Harman, and Blackman surveyed human growth hormone and human aging, including the age-related decline in GH secretion that motivates interest in secretagogue approaches. A 2006 commentary in Clinical Interventions in Aging discussed sermorelin in the context of adult-onset GH insufficiency. A small 2017 study in the American Journal of Men's Health reported that growth hormone secretagogue treatment raised serum IGF-1 in hypogonadal men.

Taken together, this is a mechanistic and diagnostic evidence base — stimulation testing, small cohorts, and reviews — rather than large confirmatory randomized outcome trials of sermorelin itself.

Sermorelin acetate was previously approved in the United States as Geref, used for diagnostic GH stimulation testing and in pediatric growth hormone deficiency. The branded product was subsequently discontinued from the U.S. market by its manufacturer, and current commercial approval status in the U.S. is best described as discontinued. Material supplied today for laboratory work is a research chemical.

Supplied lyophilized in a sealed vial. GHRH fragments are handled as moisture-sensitive peptides: keep the vial sealed until use, equilibrate refrigerated or frozen material before opening, reconstitute with an appropriate solvent, aliquot to avoid freeze-thaw cycling, and keep solutions cold and protected from light. Document the lot number alongside experimental records.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.